Rethinking the use of germline CHEK2 mutation as a marker for PARP inhibitor sensitivity.

The article presents the discussion on efficacy of poly (ADP-ribose) polymerase inhibitors in treating breast cancer with BRCA1 or BRCA2 mutations and evaluates their potential for cancers with homologous recombination deficiencies, including those with CHEK2 mutations. Topics include the role of synthetic lethality in targeting BRCA-deficient tumors, clinical trial results for PARP inhibitors; and the bioinformatics analysis of genomic markers in tumors with CHEK2 mutations.